Acryth®
Erythromycin
COMPOSITION:
Acryth® suspension: After reconstitution each 5ml suspension contains Erythromycin Ethylsuccinate USP equivalent to 125mg Erythromycin.
PHARMACOLOGICAL INFORMATION:
Pharmacological Action
Acryth® suspension is highly effective against most strains of the following microorganisms, both in vitro and in clinical infections:
Gram-positive microorganisms: Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Corynebacterium diphtheriae, Corynebacterium minutissimum and Listeria monocytogenes.
Gram-negative microorganisms: Haemophilus influenzae, Bordetella pertusis, Legionella pneumophilia, Campylobacter jejuni and Neisseria gonorrhoeae.
Other microorganisms: Mycoplasma pneumoniae, Chlamydia trachomatis, Entamoeba histolytica, Treponema pallidum and Ureaplasma urealyticum.
Mechanism of Action
Acryth® suspension inhibits protein synthesis by binding to the 23S rRNA molecule (in the 50S subunit) of the bacterial ribosome blocking the exit of the growing peptide chain of sensitive microorganisms.
CLINICAL INFORMATION:
Therapeutic Indications:
Acryth® suspension is the drug of choice in the following indications-
Alternative to a penicillin in penicillin-sensitive patients-
- Penicillin-resistant staphylococcal infections
- Alternative to a tetracycline in mycoplasma pneumonia
- Pertussis, diphtheria- especially in treatment of the carrier state
- Rheumatic fever prophylaxis
- Chronic bronchitis
- Otitis media
- Chronic prostatitis.
Dosage and Administration
Adults:
The usual dose is 250mg 6 hourly. This may be increased up to 4gm per day according to the severity of the infections.
Children
The usual regimen is 30-50mg/kg/day. In severe cases this dosage may be doubled.
Contraindications
Acryth® suspension is contraindicated in patients hypersensitive to Erythromycin.
Use in patients with impaired hepatic function
Acryth® suspension should be given with care in patients with impaired hepatic function.
Drug Interactions
Ergotamine: Concurrent use of Erythromycin & Ergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.
Warfarin: Acryth® suspension may decrease the clearance of warfarin and thus potentiate the hypoprothrombinic effect of warfarin.
Theophylline: Acryth® suspension use in patients who are receiving high doses of Theophylline may be associated with an increase in serum Theophylline levels and potential Theophylline toxicity.
Use in Pregnancy & Lactation
Acryth® suspension is a pregnancy category B drug and considered compatible with breast feeding by the American Academy of Paediatrics.
Undesirable Effects
Acryth® suspension is one of the safer antibiotics, gastrointestinal disturbances and allergy being the commonest (0.5-5%) adverse effects.
PHARMACEUTICAL INFORMATION
Storage & Conditions
Store in a cool (below 30ºC) and dry place, away from light. Keep out of reach of children.
Presentation & Packaging
Acryth® suspension: Each amber glass bottle contains dry powder for preparation of 100ml suspension.
